1A0H | B:333-437,B:565-579; E:333-437,E:565-579; B:321-332,B:438-564; E:321-332,E:438-564 | THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN |
1AB9 | C:150-245; B:16-146 | CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN |
1AFQ | C:150-245; B:16-146 | CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN COMPLEXED WITH A SYNTHETIC INHIBITOR |
1AQ7 | A:16-27,A:121-232; A:28-120,A:233-244 | TRYPSIN WITH INHIBITOR AERUGINOSIN 98-B |
1AUJ | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN COMPLEXED TO META-CYANO-BENZYLIC INHIBITOR |
1AVG | H:28-120,H:233-247; H:16-27,H:121-232 | THROMBIN INHIBITOR FROM TRIATOMA PALLIDIPENNIS |
1AZ8 | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN COMPLEXED TO BIS-PHENYLAMIDINE INHIBITOR |
1BBR | K:28-120,K:233-247; N:28-120,N:233-247; K:16-27,K:121-232; N:16-27,N:121-232; E:149B-247; H:16-149A | THE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION |
1BJU | A:16-27,A:121-232; A:28-120,A:233-245 | BETA-TRYPSIN COMPLEXED WITH ACPU |
1BJV | A:16-27,A:121-232; A:28-120,A:233-245 | BETA-TRYPSIN COMPLEXED WITH APPU |
1BTH | H:28-120,H:233-242; K:28-120,K:233-242; H:16-27,H:121-232; K:16-27,K:121-232 | STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR |
1BTP | A:16-27,A:121-232; A:28-120,A:233-245 | UNIQUE BINDING OF A NOVEL SYNTHETIC INHIBITOR, N-[3-[4-[4-(AMIDINOPHENOXY)-CARBONYL]PHENYL]-2-METHYL-2-PROPENOYL]-N-ALLYLGLYCINE METHANESULFONATE TO BOVINE TRYPSIN, REVEALED BY THE CRYSTAL STRUCTURE OF THE COMPLEX |
1BTW | A:16-27,A:121-232; A:28-120,A:233-245 | EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE |
1BTZ | A:16-27,A:121-232; A:28-120,A:233-245 | EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE |
1C1N | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1O | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1P | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1Q | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1R | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1S | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C1T | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2D | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2E | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2F | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2G | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2H | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2I | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2J | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2K | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2L | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C2M | A:16-27,A:121-232; A:28-120,A:233-245 | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
1C5P | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5Q | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5R | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5S | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5T | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5U | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C5V | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR |
1C9T | A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245; E:28-120,E:233-245; F:28-120,F:233-245 | COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN |
1CA0 | C:149-245; H:149-245; B:16-146; G:16-146 | BOVINE CHYMOTRYPSIN COMPLEXED TO APPI |
1CBW | C:149-245; H:149-245; B:16-146; G:16-146 | BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI |
1CE5 | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE |
1CGI | E:28-120,E:233-245; E:16-27,E:121-232 | THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE) |
1CGJ | E:28-120,E:233-245; E:16-27,E:121-232 | THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE) |
1CHG | A:28-120,A:233-242; A:16-27,A:121-232 | CHYMOTRYPSINOGEN,2.5 ANGSTROMS CRYSTAL STRUCTURE, COMPARISON WITH ALPHA-CHYMOTRYPSIN,AND IMPLICATIONS FOR ZYMOGEN ACTIVATION |
1CHO | G:149-245; F:16-146 | CRYSTAL AND MOLECULAR STRUCTURES OF THE COMPLEX OF ALPHA-*CHYMOTRYPSIN WITH ITS INHIBITOR TURKEY OVOMUCOID THIRD DOMAIN AT 1.8 ANGSTROMS RESOLUTION |
1D6R | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF CANCER CHEMOPREVENTIVE BOWMAN-BIRK INHIBITOR IN TERNARY COMPLEX WITH BOVINE TRYPSIN AT 2.3 A RESOLUTION. STRUCTURAL BASIS OF JANUS-FACED SERINE PROTEASE INHIBITOR SPECIFICITY |
1DLK | B:28-120,B:233-243; D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232 | CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR |
1EJM | A:16-27,A:121-232; C:16-27,C:121-232; E:16-27,E:121-232; A:28-120,A:233-245; C:28-120,C:233-245; E:28-120,E:233-245 | CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN |
1EKB | B:16-27,B:121-232; B:28-120,B:233-243 | THE SERINE PROTEASE DOMAIN OF ENTEROPEPTIDASE BOUND TO INHIBITOR VAL-ASP-ASP-ASP-ASP-LYS-CHLOROMETHANE |
1EUF | A:16-27,A:121-232; A:28-120,A:233-243 | BOVINE DUODENASE(NEW SERINE PROTEASE), CRYSTAL STRUCTURE |
1EX3 | A:28-120,A:233-243; A:16-27,A:121-232 | CRYSTAL STRUCTURE OF BOVINE CHYMOTRYPSINOGEN A (TETRAGONAL) |
1F0T | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN COMPLEXED WITH RPR131247 |
1F0U | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN COMPLEXED WITH RPR128515 |
1F2S | E:16-27,E:121-232; E:28-120,E:233-245 | CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY AT 1.8 A RESOLUTION |
1FON | A:11-111,A:228-240; B:11-111,B:228-240; A:9-10,A:112-227; B:9-10,B:112-227 | CRYSTAL STRUCTURE OF BOVINE PROCARBOXYPEPTIDASE A-S6 SUBUNIT III, A HIGHLY STRUCTURED TRUNCATED ZYMOGEN E |
1G36 | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN INHIBITOR COMPLEX |
1G3B | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE MAGNESIUM(II) CHELATE |
1G3C | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF BASE IRON(III) CHELATE |
1G3D | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE COPPER (II) CHELATE |
1G3E | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF-BASE COPPER (II) CHELATE |
1G9I | E:16-27,E:121-232; E:28-120,E:233-245 | CRYSTAL STRUCTURE OF BETA-TRYSIN COMPLEX IN CYCLOHEXANE |
1GBT | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURE OF AN ACYL-ENZYME INTERMEDIATE DURING CATALYSIS: (GUANIDINOBENZOYL) TRYPSIN |
1GCD | A:28-120,A:233-243; A:16-27,A:121-232 | REFINED CRYSTAL STRUCTURE OF "AGED" AND "NON-AGED" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN |
1GG6 | C:149-245; B:16-146 | CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-PHENYLALANINE TRIFLUOROMETHYL KETONE BOUND AT THE ACTIVE SITE |
1GGD | C:151-245; B:16-146 | CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-LEUCIL-PHENYLALANINE ALDEHYDE BOUND AT THE ACTIVE SITE |
1GHA | G:151-245; F:16-146 | A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN |
1GHZ | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI0 | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI1 | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI2 | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI3 | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI4 | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI5 | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GI6 | A:16-27,A:121-232; A:28-120,A:233-245 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE |
1GJ6 | A:16-27,A:121-232; A:28-120,A:233-245 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS |
1GMC | G:151-245; F:16-146 | THE X-RAY CRYSTAL STRUCTURE OF THE TETRAHEDRAL INTERMEDIATE OF GAMMA-CHYMOTRYPSIN IN HEXANE |
1GMD | G:151-245; F:16-146 | X-RAY CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN HEXANE |
1GMH | G:150-245; F:16-146 | REFINED CRYSTAL STRUCTURE OF "AGED" AND "NON-AGED" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN |
1HJA | C:149-245; B:16-146 | LYS 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH ALPHA-CHYMOTRYPSIN |
1HRT | H:28-120,H:233-247; H:16-27,H:121-232 | THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8 ANGSTROMS RESOLUTION |
1ID5 | H:28-120,H:233-244; H:16-27,H:121-232 | CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEX WITH PROTEASE INHIBITOR ECOTIN |
1J8A | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF BENZAMIDINE INHIBITED BOVINE PANCREATIC TRYPSIN AT 105K TO 1.21A RESOLUTION FROM LABORATORY SOURCE WITH HIGH NUMBER OF WATERS MODELLED |
1JIR | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF TRYPSIN COMPLEX WITH AMYLAMINE IN CYCLOHEXANE |
1JRS | A:16-27,A:121-232; A:28-120,A:233-245 | HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN |
1JRT | A:16-27,A:121-232; A:28-120,A:233-245 | HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN |
1K1I | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN-INHIBITOR COMPLEX |
1K1J | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN-INHIBITOR COMPLEX |
1K1L | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN-INHIBITOR COMPLEX |
1K1M | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN-INHIBITOR COMPLEX |
1K1N | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN-INHIBITOR COMPLEX |
1K1O | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN-INHIBITOR COMPLEX |
1K1P | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN-INHIBITOR COMPLEX |
1K2I | 1:28-120,1:233-243; 1:18-27,1:121-232 | CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN COMPLEX WITH 7-HYDROXYCOUMARIN |
1KIG | H:16-27,H:121-232; H:28-120,H:233-246 | BOVINE FACTOR XA |
1LQE | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF TRYPSIN IN COMPLEX WITH 79. |
1MAX | A:16-27,A:121-232; A:28-120,A:233-245 | BETA-TRYPSIN PHOSPHONATE INHIBITED |
1MAY | A:16-27,A:121-232; A:28-120,A:233-245 | BETA-TRYPSIN PHOSPHONATE INHIBITED |
1MKW | H:28-120,H:233-243; K:28-120,K:233-243; H:16-27,H:121-232; K:16-27,K:121-232 | THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING |
1MKX | H:28-120,H:233-243; K:28-120,K:233-243; H:16-27,H:121-232; K:16-27,K:121-232 | THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING |
1MTN | C:149-245; G:149-245; B:16-146; F:16-146 | BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION |
1MTS | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN |
1MTU | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN |
1MTV | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN |
1MTW | A:16-27,A:121-232; A:28-120,A:233-245 | FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN |
1N6X | A:16-27,A:121-232; A:28-120,A:233-245 | RIP-PHASING ON BOVINE TRYPSIN |
1N6Y | A:16-27,A:121-232; A:28-120,A:233-245 | RIP-PHASING ON BOVINE TRYPSIN |
1N8O | C:149-245; B:16-146 | CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BOVINE CHYMOTRYPSIN AND ECOTIN |
1NC6 | A:16-27,A:121-232; A:28-120,A:233-245 | POTENT, SMALL MOLECULE INHIBITORS OF HUMAN MAST CELL TRYPTASE. ANTI-ASTHMATIC ACTION OF A DIPEPTIDE-BASED TRANSITION STATE ANALOGUE CONTAINING BENZOTHIAZOLE KETONE |
1NTP | A:16-27,A:121-232; A:28-120,A:233-245 | USE OF THE NEUTRON DIFFRACTION H/D EXCHANGE TECHNIQUE TO DETERMINE THE CONFORMATIONAL DYNAMICS OF TRYPSIN |
1O2H | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2I | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2J | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2K | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2L | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2M | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2N | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2O | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2P | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2Q | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2R | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2S | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2T | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2U | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2V | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2W | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2X | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2Y | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O2Z | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O30 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O31 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O32 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O33 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O34 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O35 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O36 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O37 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O38 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O39 | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3A | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3B | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3C | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3D | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3E | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3F | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3G | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3H | A:16-27,A:121-232; A:28-120,A:233-244 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3I | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3J | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3K | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3L | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3M | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3N | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1O3O | A:16-27,A:121-232; A:28-120,A:233-245 | ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS |
1OX1 | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF THE BOVINE TRYPSIN COMPLEX WITH A SYNTHETIC 11 PEPTIDE INHIBITOR |
1OYQ | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN INHIBITOR COMPLEX |
1P2I | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN |
1P2J | A:16-27,A:121-232; A:28-120,A:233-242 | STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN |
1P2K | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN |
1P2M | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN |
1P2N | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN |
1P2O | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN |
1P2Q | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN |
1PPE | E:16-27,E:121-232; E:28-120,E:233-245 | THE REFINED 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND CMTI-I, A TRYPSIN INHIBITOR FROM SQUASH SEEDS (CUCURBITA MAXIMA): TOPOLOGICAL SIMILARITY OF THE SQUASH SEED INHIBITORS WITH THE CARBOXYPEPTIDASE A INHIBITOR FROM POTATOES |
1PYT | C:428-520,C:633-645; D:728-820,D:933-944; C:416-427,C:521-632; D:716-727,D:821-932 | TERNARY COMPLEX OF PROCARBOXYPEPTIDASE A, PROPROTEINASE E, AND CHYMOTRYPSINOGEN C |
1QA0 | A:7-18,A:109-216; A:19-108,A:217-229 | BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX |
1QB1 | A:7-18,A:109-216; A:19-108,A:217-229 | BOVINE TRYPSIN WITH 1-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDIN-4-YL]PIPERIDINE-3-CARBOXYLIC ACID (ZK-806974) |
1QB6 | A:7-18,A:109-216; A:19-108,A:217-229 | BOVINE TRYPSIN 3,3'-[3,5-DIFLUORO-4-METHYL-2, 6-PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK-805623) COMPLEX |
1QB9 | A:7-18,A:109-216; A:19-108,A:217-229 | BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX |
1QBN | A:7-18,A:109-216; A:19-108,A:217-229 | BOVINE TRYPSIN 2-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDINE-4-CARBOXYLIC ACID (ZK-806688) COMPLEX |
1QBO | A:7-18,A:109-216; A:19-108,A:217-229 | BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX |
1QCP | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF THE RWJ-51084 BOVINE PANCREATIC BETA-TRYPSIN AT 1.8 A |
1RXP | A:16-27,A:121-232; A:28-120,A:233-245 | STRUCTURE OF TRYPSIN (ORTHORHOMBIC) WITH 1-(4-TERT-BUTYLCARBAMOYL- PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO-PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID |
1S0Q | A:660-671,A:762-869; A:672-761,A:870-881 | NATIVE BOVINE PANCREATIC TRYPSIN |
1S0R | A:1-12,A:103-210; A:13-102,A:211-222 | BOVINE PANCREATIC TRYPSIN INHIBITED WITH BENZAMIDINE AT ATOMIC RESOLUTION |
1SBW | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF MUNG BEAN INHIBITOR LYSINE ACTIVE FRAGMENT COMPLEX WITH BOVINE BETA-TRYPSIN AT 1.8A RESOLUTION |
1SFI | A:16-27,A:121-232; A:28-120,A:233-245 | HIGH RESOLUTION STRUCTURE OF A POTENT, CYCLIC PROTEASE INHIBITOR FROM SUNFLOWER SEEDS |
1T7C | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | CRYSTAL STRUCTURE OF THE P1 GLU BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX |
1T8L | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX |
1T8M | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | CRYSTAL STRUCTURE OF THE P1 HIS BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX |
1T8N | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX |
1T8O | A:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232 | CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX |
1TAW | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE TRYPSIN COMPLEXED TO APPI |
1TBQ | H:28-120,H:233-247; K:28-120,K:233-247; H:16-27,H:121-232; K:16-27,K:121-232 | CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN |
1TBR | H:28-120,H:233-247; K:28-120,K:233-247; H:16-27,H:121-232; K:16-27,K:121-232 | CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN |
1TGB | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF BOVINE TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. II. CRYSTALLOGRAPHIC REFINEMENT, REFINED CRYSTAL STRUCTURE AND COMPARISON WITH BOVINE TRYPSIN |
1TGC | A:16-27,A:121-232; A:28-120,A:233-245 | ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY |
1TGN | A:17-27,A:121-232; A:28-120,A:233-245 | STRUCTURE OF BOVINE TRYPSINOGEN AT 1.9 ANGSTROMS RESOLUTION |
1TGS | Z:16-27,Z:121-232; Z:28-120,Z:233-245 | THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN PANCREATIC SECRETORY INHIBITOR (KAZAL TYPE) AND TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. STRUCTURE SOLUTION, CRYSTALLOGRAPHIC REFINEMENT AND PRELIMINARY STRUCTURAL INTERPRETATION |
1TIO | A:16-27,A:121-232; A:28-120,A:233-245 | HIGH PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE |
1TLD | A:16-27,A:121-232; A:28-120,A:233-245 | CRYSTAL STRUCTURE OF BOVINE BETA-TRYPSIN AT 1.5 ANGSTROMS RESOLUTION IN A CRYSTAL FORM WITH LOW MOLECULAR PACKING DENSITY. ACTIVE SITE GEOMETRY, ION PAIRS AND SOLVENT STRUCTURE |
1TNG | A:16-27,A:121-232; A:28-120,A:233-245 | PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS |
1TNH | A:16-27,A:121-232; A:28-120,A:233-245 | PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS |
1TNI | A:16-27,A:121-232; A:28-120,A:233-245 | PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS |
1TNJ | A:16-27,A:121-232; A:28-120,A:233-245 | PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS |
1TNK | A:16-27,A:121-232; A:28-120,A:233-245 | PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS |
1TNL | A:16-27,A:121-232; A:28-120,A:233-245 | PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS |
1TOC | B:28-120,B:233-247; D:28-120,D:233-247; F:28-120,F:233-247; H:28-120,H:233-247; B:16-27,B:121-232; D:16-27,D:121-232; F:16-27,F:121-232; H:16-27,H:121-232 | STRUCTURE OF SERINE PROTEINASE |
1TPA | E:16-27,E:121-232; E:28-120,E:233-245 | THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS |
1TPO | A:16-27,A:121-232; A:28-120,A:233-245 | THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS |
1TPP | A:16-27,A:121-232; A:28-120,A:233-245 | THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS |
1TPS | A:16-27,A:121-232; A:28-120,A:233-245 | ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION |
1TX7 | A:16-27,A:121-232; A:28-120,A:233-244 | BOVINE TRYPSIN COMPLEXED WITH P-AMIDINOPHENYLMETHYLPHOSPHINIC ACID (AMPA) |
1TX8 | A:16-27,A:121-232; A:28-120,A:233-244 | BOVINE TRYPSIN COMPLEXED WITH AMSO |
1TYN | A:16-27,A:121-232; A:28-120,A:233-245 | ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS |
1UCY | K:28-120,K:233-247; N:28-120,N:233-247; K:16-27,K:121-232; N:16-27,N:121-232; E:149B-247; H:16-149A | THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7-19). THREE COMPLEXES, ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN |
1UVT | H:28-120,H:233-241; H:16-27,H:121-232 | BOVINE THROMBIN--BM14.1248 COMPLEX |
1UVU | H:28-120,H:233-237; H:16-27,H:121-232 | BOVINE THROMBIN--BM12.1700 COMPLEX |
1V2J | T:16-27,T:121-232; T:28-120,T:233-245 | BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI) BT.C1 |
1V2K | T:16-27,T:121-232; T:28-120,T:233-245 | FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D2 |
1V2L | T:16-27,T:121-232; T:28-120,T:233-245 | BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D1 |
1V2M | T:16-27,T:121-232; T:28-120,T:233-245 | BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.A1 |
1V2N | T:16-27,T:121-232; T:28-120,T:233-245 | POTENT FACTOR XA INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(99/175/190)BT |
1V2O | T:16-27,T:121-232; T:28-120,T:233-245 | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.B4 |
1V2P | T:16-27,T:121-232; T:28-120,T:233-245 | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.A4 |
1V2Q | T:16-27,T:121-232; T:28-120,T:233-245 | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSWI)BT.B4 |
1V2R | T:16-27,T:121-232; T:28-120,T:233-245 | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)BT.B4 |
1V2S | T:16-27,T:121-232; T:28-120,T:233-245 | BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.D1 |
1V2T | T:16-27,T:121-232; T:28-120,T:233-245 | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.B4 |
1V2U | T:16-27,T:121-232; T:28-120,T:233-245 | BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARINAT X(SSAI) BT.D1 |
1V2V | T:16-27,T:121-232; T:28-120,T:233-245 | BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI) BT.C1 |
1V2W | T:16-27,T:121-232; T:28-120,T:233-245 | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI)BT.B4 |
1VGC | C:151-245; B:16-146 | GAMMA-CHYMOTRYPSIN L-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX |
1VIT | H:28-120,H:233-247; H:16-27,H:121-232; G:149B-247; F:16-149A | THROMBIN:HIRUDIN 51-65 COMPLEX |
1XUF | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN-BABIM-ZN+2, PH 8.2 |
1XUG | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN-BABIM-ZN+2, PH 8.2 |
1XUH | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN-KETO-BABIM-CO+2, PH 8.2 |
1XUI | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN-KETO-BABIM, ZN+2-FREE, PH 8.2 |
1XUJ | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN-KETO-BABIM-ZN+2, PH 8.2 |
1XUK | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN-BABIM-SULFATE, PH 5.9 |
1Y3U | A:16-27,A:121-232; A:28-120,A:233-244 | TRYPSIN INHIBITOR COMPLEX |
1Y3V | A:16-27,A:121-232; A:28-120,A:233-244 | TRYPSIN INHIBITOR COMPLEX |
1Y3W | A:16-27,A:121-232; A:28-120,A:233-244 | TRYPSIN INHIBITOR COMPLEX |
1Y3X | A:16-27,A:121-232; A:28-120,A:233-244 | TRYPSIN INHIBITOR COMPLEX |
1Y3Y | A:16-27,A:121-232; A:28-120,A:233-244 | TRYPSIN INHIBITOR COMPLEX |
1YCP | H:28-120,H:233-242; H:16-27,H:121-232; M:150-243; K:16-146 | THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16 |
1YP9 | A:253-27,A:121-232; A:28-120,A:233-244 | TRYPSIN INHIBITOR COMPLEX |
1YPH | E:149-245; F:149-245; C:16-146; D:16-146 | HIGH RESOLUTION STRUCTURE OF BOVINE ALPHA-CHYMOTRYPSIN |
1YYY | 1:16-27,1:121-232; 1:28-120,1:233-245 | TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES |
1ZR0 | A:16-27,A:121-232; C:16-27,C:121-232; A:28-120,A:233-245; C:28-120,C:233-245 | CRYSTAL STRUCTURE OF KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR-2 WITH BOVINE TRYPSIN |
1ZZZ | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES |
2A1D | B:28-120,B:233-247; F:28-120,F:233-247; B:16-27,B:121-232; F:16-27,F:121-232 | STAPHYLOCOAGULASE BOUND TO BOVINE THROMBIN |
2A7H | A:7-18,A:109-216; A:19-108,A:217-228 | ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY, PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH |
2AGE | X:16-27,X:121-232; X:28-120,X:233-244 | SUCCINYL-AAPR-TRYPSIN ACYL-ENZYME AT 1.15 A RESOLUTION |
2AGG | X:16-27,X:121-232; X:28-120,X:233-244 | SUCCINYL-AAPK-TRYPSIN ACYL-ENZYME AT 1.28 A RESOLUTION |
2AGI | X:16-27,X:121-232; X:28-120,X:233-244 | THE LEUPEPTIN-TRYPSIN COVALENT COMPLEX AT 1.14 A RESOLUTION |
2AH4 | X:16-27,X:121-232; X:28-120,X:233-244 | GUANIDINOBENZOYL-TRYPSIN ACYL-ENZYME AT 1.13 A RESOLUTION |
2AYW | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN TRYPSIN AND A DESIGNED SYNTHETIC HIGHLY POTENT INHIBITOR IN THE PRESENCE OF BENZAMIDINE AT 0.97 A RESOLUTION |
2BTC | E:16-27,E:121-232; E:28-120,E:233-245 | BOVINE TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II) |
2BZA | A:16-27,A:121-232; A:28-120,A:233-245 | BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZYLAMINE |
2CGA | A:28-120,A:233-245; B:28-120,B:233-245; A:16-27,A:121-232; B:16-27,B:121-232 | BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION |
2CHA | C:149-245; G:149-245; B:16-146; F:16-146 | THE STRUCTURE OF CRYSTALLINE ALPHA-CHYMOTRYPSIN, $V.THE ATOMIC STRUCTURE OF TOSYL-ALPHA-CHYMOTRYPSIN AT 2 ANGSTROMS RESOLUTION |
2D8W | A:7-18,A:109-216; A:19-108,A:217-228 | STRUCTURE OF HYPER-VIL-TRYPSIN |
2F3C | E:16-27,E:118-225; E:28-117,E:226-237 | CRYSTAL STRUCTURE OF INFESTIN 1, A KAZAL-TYPE SERINEPROTEASE INHIBITOR, IN COMPLEX WITH TRYPSIN |
2FI3 | E:16-27,E:121-232; E:28-120,E:233-244 | CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER, CYS38->SER) IN COMPLEX WITH TRYPSIN |
2FI4 | E:16-27,E:121-232; E:28-120,E:233-244 | CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER) IN COMPLEX WITH TRYPSIN |
2FI5 | E:16-27,E:121-232; E:28-120,E:233-244 | CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS38->SER) IN COMPLEX WITH TRYPSIN |
2FTL | E:16-27,E:121-232; E:28-120,E:233-244 | CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BPTI AT 100K |
2FTM | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH THE BPTI VARIANT (TYR35->GLY) |
2FX4 | A:16-27,A:121-232; A:28-120,A:233-244 | BOVINE TRYPSIN BOUND BY 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME COMPLEX |
2FX6 | A:16-27,A:121-232; A:28-120,A:233-244 | BOVINE TRYPSIN COMPLEXED WITH 2-AMINOBENZAMIDAZOLE |
2G55 | A:7-18,A:109-216; A:19-108,A:217-228 | ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P3121) |
2G5N | A:7-18,A:109-216; A:19-108,A:217-228 | INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN |
2G5V | A:7-18,A:109-216; A:19-108,A:217-228 | INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN |
2G81 | E:16-27,E:121-232; E:28-120,E:233-244 | CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM VIGNA UNGUICULATA SEEDS IN COMPLEX WITH BETA-TRYPSIN AT 1.55 ANGSTRONS RESOLUTION |
2G8T | A:7-18,A:109-216; A:19-108,A:217-228 | INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN |
2GCH | G:151-245; F:16-146 | REFINED CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN AT 1.9 ANGSTROMS RESOLUTION |
2GMT | C:151-245; B:16-146 | THREE-DIMENSIONAL STRUCTURE OF CHYMOTRYPSIN INACTIVATED WITH (2S) N-ACETYL-L-ALANYL-L-PHENYLALANYL-CHLOROETHYL KETONE: IMPLICATIONS FOR THE MECHANISM OF INACTIVATION OF SERINE PROTEASES BY CHLOROKETONES |
2ILN | A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-244; B:28-120,B:233-244 | CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM SNAIL MEDIC SEEDS IN COMPLEX WITH BOVINE TRYPSIN |
2O9Q | A:19-30,A:121-228; A:31-120,A:229-241 | THE CRYSTAL STRUCTURE OF BOVINE TRYPSIN COMPLEXED WITH A SMALL INHIBITION PEPTIDE ORB2K |
2ODY | B:28-120,B:233-243; D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232 | THROMBIN-BOUND BOOPHILIN DISPLAYS A FUNCTIONAL AND ACCESSIBLE REACTIVE-SITE LOOP |
2OTV | A:16-27,A:121-238; A:28-120,A:239-250 | CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE TRYPSIN AND NICOTINAMIDE AT 1.56 A RESOLUTION |
2OXS | A:16-27,A:121-232; A:28-120,A:233-244 | CRYSTAL STRUCTURE OF THE TRYPSIN COMPLEX WITH BENZAMIDINE AT HIGH TEMPERATURE (35 C) |
2P8O | C:151-245; B:16-146 | CRYSTAL STRUCTURE OF A BENZOHYDROXAMIC ACID/VANADATE COMPLEX BOUND TO CHYMOTRYPSIN A |
2PLX | A:16-27,A:121-232; A:28-120,A:233-245 | TRYPSIN COMPLEXED TO A SYNTHETIC PEPTIDE FROM VERONICA HEDERIFOLIA |
2PTC | E:16-27,E:121-232; E:28-120,E:233-245 | THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS |
2PTN | A:16-27,A:121-232; A:28-120,A:233-245 | ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY |
2TGA | A:16-27,A:121-232; A:28-120,A:233-245 | ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY |
2TGD | A:17-27,A:121-232; A:28-120,A:233-245 | LACK OF THE TRANSITION STATE STABILIZATION SITE IS A FACTOR IN THE INACTIVITY OF TRYPSINOGEN, A SERINE PROTEASE ZYMOGEN. STRUCTURE OF DFP INHIBITED BOVINE TRYPSINOGEN AT 2.1 ANGSTROMS RESOLUTION |
2TGP | Z:16-27,Z:121-232; Z:28-120,Z:233-245 | THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS |
2TIO | A:16-27,A:121-232; A:28-120,A:233-245 | LOW PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE |
2VGC | C:151-245; B:16-146 | GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX |
3BTD | E:16-27,E:121-232; E:28-120,E:233-244 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN THE BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI. |
3BTE | E:16-27,E:121-232; E:28-120,E:233-243 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI. |
3BTF | E:16-27,E:121-232; E:28-120,E:233-245 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI. |
3BTG | E:16-27,E:121-232; E:28-120,E:233-244 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI |
3BTH | E:16-27,E:121-232; E:28-120,E:233-242 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI |
3BTK | E:16-27,E:121-232; E:28-120,E:233-243 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI |
3BTM | E:16-27,E:121-232; E:28-120,E:233-244 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI |
3BTQ | E:16-27,E:121-232; E:28-120,E:233-244 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI |
3BTT | E:16-27,E:121-232; E:28-120,E:233-244 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI |
3BTW | E:16-27,E:121-232; E:28-120,E:233-243 | THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI |
3GCT | G:151-245; F:16-146 | STRUCTURE OF GAMMA-*CHYMOTRYPSIN IN THE RANGE $P*H 2.0 TO $P*H 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW $P*H |
3PTB | A:16-27,A:121-232; A:28-120,A:233-245 | THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS |
3PTN | A:16-27,A:121-232; A:28-120,A:233-245 | ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY |
3TPI | Z:16-27,Z:121-232; Z:28-120,Z:233-245 | THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS |
3VGC | C:151-245; B:16-146 | GAMMA-CHYMOTRYPSIN L-NAPHTHYL-1-ACETAMIDO BORONIC ACID ACID INHIBITOR COMPLEX |
4CHA | C:149-245; G:149-245; B:16-146; F:16-146 | STRUCTURE OF ALPHA-*CHYMOTRYPSIN REFINED AT 1.68 ANGSTROMS RESOLUTION |
4GCH | G:151-245; F:16-146 | STRUCTURE AND ACTIVITY OF TWO PHOTOREVERSIBLE CINNAMATES BOUND TO CHYMOTRYPSIN |
4TPI | Z:16-27,Z:121-232; Z:28-120,Z:233-245 | THE REFINED 2.2-ANGSTROMS (0.22-NM) X-RAY CRYSTAL STRUCTURE OF THE TERNARY COMPLEX FORMED BY BOVINE TRYPSINOGEN, VALINE-VALINE AND THE ARG15 ANALOGUE OF BOVINE PANCREATIC TRYPSIN INHIBITOR |
4VGC | C:151-245; B:16-146 | GAMMA-CHYMOTRYPSIN D-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX |
5CHA | C:149-245; G:149-245; B:16-146; F:16-146 | THE REFINEMENT AND THE STRUCTURE OF THE DIMER OF ALPHA-*CHYMOTRYPSIN AT 1.67-*ANGSTROMS RESOLUTION |
5GCH | G:151-245; F:16-146 | CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN |
5PTP | A:16-27,A:121-232; A:28-120,A:233-244 | STRUCTURE OF HYDROLASE (SERINE PROTEINASE) |
6CHA | C:149-245; G:149-245; B:16-146; F:16-146 | STRUCTURE OF A TETRAHEDRAL TRANSITION STATE COMPLEX OF ALPHA-*CHYMOTRYPSIN AT 1.8-*ANGSTROMS RESOLUTION |
6GCH | G:151-245; F:16-146 | STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS |
7GCH | G:151-245; F:16-146 | STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS |
8GCH | G:150-245; F:16-146 | GAMMA-CHYMOTRYPSIN IS A COMPLEX OF ALPHA-CHYMOTRYPSIN WITH ITS OWN AUTOLYSIS PRODUCTS |